就职医院:哈佛大学医学院附属麻省总医院
科  室:内科
职  称:哈佛大学医学院副教授
擅长领域:淋巴瘤;非霍奇金淋巴瘤(NHL);霍奇金淋巴瘤;白血病


临床兴趣:

Jeremy Slade Abramson博士主要致力于非霍奇金淋巴瘤(NHL),霍奇金淋巴瘤(淋巴肉芽肿病(CLL),艾滋病导致的淋巴瘤,骨髓移植后淋巴细胞增生性疾病(PTLD)。),慢性淋巴细胞白血病

医学教育背景:

芒特西奈医学院临床医学博士(MD)

麻省总医院住院医师

布列根和妇女医院研究员

丹娜法伯癌症研究院研究员

委员户认证:

美国内科委员会血液病委员会委员

美国内科委员会内科肿瘤学委员会委员

个人简介:

Jeremy Slade Abramson博士是麻省总医院癌症中心淋巴瘤科Jo Ann Hagler主席和科主任,他也是哈佛大学医学院助理教授。他于纽约芒特西奈医学院取得临床医学博士学位。

Jeremy Slade Abramson博士最擅长的诊治领域是恶性淋巴瘤,包括所有的非霍奇金淋巴瘤(NHL)(B-淋巴细胞、T-淋巴细胞),霍奇金淋巴瘤(淋巴肉芽肿病),慢性淋巴细胞性白血病(CLL)。他的研究包括不断开发对于这些疾病的新的靶向治疗,设计并指导新的治疗这些癌症方法的临床试验。

Jeremy Slade Abramson博士发表了大量的关于白血病的学术论文,参与多本书中相关章节的编写,在白血病和淋巴瘤治疗领域成就斐然。

目前在研项目:

Designs and conducts clinical trials of novel therapies for the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia (CLL).

近期发表的具有代表性的学术论文:

Abramson JS and Shipp MA. Advances in the biology, natural history and therapy of diffuse large B-cell lymphoma. Blood 2005.



Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis and management. oncologist 2006.



Abramson JS, Chatterji M et al. A 51-year-old woman with splenomegaly and anemia. N Engl J Med 2008.



Abramson JS, Chen W, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haem 2009.



Abramson JS. Approach to the Patient with Lymphoma. In: Goroll AH and Mulley AG, editors. Primary Care Medicine 6th ed. LWW 2009.



Abramson JS, Digumarthy S et al. A 56-Year-Old Woman with Fever, Rash, and Lymphadenopathy. N Engl J Med 2009.



Abramson JS and Scadden DT. Neoplasms in Acquired Immunodeficiency Syndrome. In: Kufe DW, et al. editors. Cancer Medicine 8. BC Decker 2010.



Canellos GP, Abramson JS et al. Treatment of favorable, limited-stage Hodgkins lymphoma with chemotherapy without consolidation by radiation therapy. J Clin oncol 2010.



Abramson JS, Hellmann M et al. Intravenous Methotrexate as CNS prophylaxis is associated with a low risk of CNS recurrence in high risk patients with Diffuse Large B Cell Lymphoma. Cancer 2010.



Barnes JA... andAbramson JS. evaluation of the addition of Ritiximab to CODOX-M/IVAC for Burkitt's Lymphoma. Ann oncol 2011.



Barnes JA... andAbramson JS. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin lymphoma. Ann oncol 2011.



Zelenetz AD, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkins lymphomas. J NCCN 2011.